GSK360A

GSK360A is a potent and orally active HIF-PHD inhibitor with IC50 values of 10, 100, and 126 nM for PHD1, PHD2, and PHD3, respectively. GSK360A activates the HIF-1 alpha pathway and protect the failing heart after myocardial infarction (MI) [1].

Product Specifications

CAS Number

[931399-19-8]

UNSPSC

12352005

Target

HIF/HIF Prolyl-Hydroxylase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/gsk360a.html

Purity

99.90

Solubility

10 mM in DMSO

Smiles

O=C(CNC(C1=C(C2=C(C=CC(F)=C2)N(C1=O)CCC3CC3)O)=O)O

Molecular Formula

C17H17FN2O5

Molecular Weight

348.33

References & Citations

[1]Bao W, et, al. Chronic inhibition of hypoxia-inducible factor prolyl 4-hydroxylase improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat. J Cardiovasc Pharmacol. 2010 Aug;56 (2) :147-55.